Replies to post #1703 on Galectin Therapeutics Inc. (GALT)

[pugdaddy]

I've noticed (rather consistently) that the posters who are 'trashing' GALT are those who appear to have little if any understanding of the science. As one who has researched and extensively studied the science, I believe in the efficacy of GR-MD-02. Moreover, I'm very familiar with the Fibroscan (ultrasound elastometry) radiology - and with the fibrosis blood marker tests such as FibroSure. Anyone who's screaming about "biopsies" doesn't realize that they're seldom needed anymore. The cohort results showed that GR-MD-02 infusion produced marked reduction in serum A2M levels. Any liver specialist knows that this (A2M reduction) is consistent with improvement in liver function. It will take a while to sort this all out to the satisfaction of the FDA et al, but these early indications are that GALT has a winner on its hands.